Tech Company Financing Transactions
Curevo Vaccine Funding Round
RA Capital, Adjuvant Capital and EN Investment participated in a $60 million Series A funding round for Curevo Vaccine. The financing round was announced on 2/10/2022.
Transaction Overview
Company Name
Announced On
2/10/2022
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21540 - 30th Dr. Southeast 260
Bothell, WA 98021
USA
Bothell, WA 98021
USA
Phone
Website
Email Address
Overview
Curevo Vaccine is a clinical-stage biotechnology company, focused on bringing new generation adjuvanted subunit vaccines to market. We combine excellence in protein and adjuvant biology to create vaccines of global importance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Simeon
Chief Financial Officer
Gregory Curhan
VP - General Counsel
Julie Brooks
VP - Operations
Lisa Shelton
VP - Operations
Andrea Wang
Browse more venture capital transactions:
Prev: 2/10/2022: Midnite venture capital transaction
Next: 2/10/2022: Doing Things Media venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs